Medicines & supplements – Current GIS Alerts 2026
Found 734 alerts in the Medicines & supplements category. Check batch numbers, shops, and hazard information.
Common hazards in this category
All recalled products
Euthyrox N 25
The acceptance limit specified in the quality specification for this parameter (maximum active substance content) was exceeded. Therefore, a risk to human health from leaving this batch of the medicinal product on the market cannot be excluded. Potential effects: levothyroxine overdose, hormonal disturbances, adverse reactions.
Mivacron
The presence of glass particles in ampoules of an intravenously administered medicine cannot be excluded, which may cause direct negative health consequences for patients, including vascular damage and embolic events. Potential effects: vessel damage, thromboembolic complications, acute reactions, life‑threatening events.
Nimbex
A possible presence of glass particles was identified in ampoules of Nimbex solution for intravenous injection, which may cause direct adverse health consequences and pose a risk to patients’ health or life. Potential effects: vascular damage, embolism, inflammation, acute complications, life‑threatening events.
Benlek
The product does not meet quality requirements due to a failed test of “Chromatographic purity of thiamine hydrochloride: any unspecified impurity”; the impurity was identified as a metamizole derivative. Potential effects: possible unpredictable adverse reactions and reduced treatment efficacy.
Kidofen
Exceedance of the quality specification limit for the single impurity parameter was found, which may affect the effectiveness and safety of the medicine; a risk to children’s health cannot be excluded. Potential effects: possible adverse reactions, lack of efficacy, complications in children.
Signopam
Reduced temazepam release may lead to insufficient patient exposure, lack of hypnotic and sedative efficacy, and risk of inappropriate treatment, including dose escalation and variability of effect. Potential effects: reduced treatment efficacy, need to change therapy.
Rivaldo
Failure to meet quality requirements consists in exceeding the lower limit for active substance content and exceeding the upper limit for average capsule mass, creating a real risk to patients’ health due to lack of the intended efficacy of the product. Potential effects: lack of treatment efficacy, worsening of patients’ health.
Liv 52
There is no clear description of a specific hazard in the provided part of the decision; however, the medicinal product was withdrawn from the market and its placing on the market was prohibited in Poland, indicating significant concerns about its quality or safety. Potential effects: lack of treatment efficacy or adverse reactions.
Cozaar
Damage to the immediate packaging (blister foil cracking) was found, causing loss of tightness and no guarantee of product quality, which may lead to tablet degradation and exposure to moisture and contaminants. Potential effects: reduced treatment efficacy, adverse effects.
POLIPARIN 25000 IU/5 ml, Heparin sodium, solution for injection and infusion, 25000 IU/5 ml, 5 ml x 1 vial
Non‑compliances were observed involving “nodular clotting after administration of the product in several patients”, with no confirmed cause, which may directly lead to negative health consequences for patients. Potential effects: thrombosis, vascular complications, health risk.
Lipidem
Aggregates were found in the lipid emulsion; intravenous administration of a defective batch without a filter may lead to fat embolism in the capillary vessels of the lungs. Potential effects: pulmonary embolism, respiratory complications, life-threatening condition.
Seronil
It was found that in batches 2127580 and 2132779 the level of the impurity N-nitroso fluoxetine exceeds the temporary limit acceptable to EMA, which means loss of the required quality of the medicine and a potential risk to human health. Potential effects: possible carcinogenic effects with long-term use, impaired treatment efficacy.
Seronil
Exceedance of the temporary limit for the N-nitroso fluoxetine impurity in tablets was found, indicating loss of the required medicinal quality and possible negative impact on efficacy and safety of use. Potential effects: possible toxicity, increased cancer risk, lack of treatment safety.
Fingolimod Stada
Stability studies showed an active substance content lower than required, which, according to the Chief Pharmaceutical Inspector, poses a real risk to patients’ health due to the lack of the intended efficacy of the medicinal product. Potential effects: lack of treatment efficacy and possible worsening of the disease.
Ibuprofen Dr. Max
A justified suspicion of non-compliance with quality requirements concerned the loss on drying parameter for batch DQ2011, which could indicate deviations in capsule quality, but subsequent analyses showed compliance with the extended specification. Potential effects: no significant health effects for patients.
Hydrocortisone (Hydrocortisonum) 100 g/100 g, 1 g pack
In this case it cannot be clearly ruled out that Lidocaine hydrochloride monohydrate raw material was mixed with Hydrocortisone. Consequently, there is a risk of preparing a medicine with a qualitative composition inconsistent with the prescription, which endangers patients’ health and life. Potential effects: lack of treatment efficacy, adverse effects related to the wrong active substance.
Atorvastatin Medical Valley
A quality defect of the tablets was found – surface erosion, defects and uneven coating, which may affect critical quality attributes of the medicine, especially those changing during storage. Potential effects: reduced treatment efficacy or unpredictable drug action.
Hyalgan
The lack of ATD protection on the outer packaging prevents verification of package tampering and full authenticity of the medicine, creating a risk of easy opening of the carton and replacement of the original product with another. Potential effects: medicine falsification, lack of efficacy, complications after injection.
Inuprin Forte
Crystalline sucrose precipitate was observed, which may reduce its concentration in the syrup and the effectiveness of its preservative action, thereby endangering adequate microbiological purity of the medicine, especially during storage after opening. Potential effects: contamination or spoilage of the syrup, possible reduced treatment efficacy.
Bupivacaine WZF Spinal 0,5% Heavy
Insoluble contaminants were detected in some ampoules of the injection solution, which may affect the quality, efficacy and safety of the medicinal product. Potential effects: complications during spinal anaesthesia, inflammatory reactions, lack of efficacy, serious health complications.
What to do if you bought a recalled product?
If you have purchased any of the products listed above, stop using or consuming them immediately. You can return the product to the store where you bought it for a full refund. Keep the receipt if possible, but most stores will accept returns even without one.